Roquette to debut expanded excipient portfolio at CPHI 2025
Key takeaways
- Roquette will debut its expanded excipient portfolio at CPHI 2025, following its IFF Pharma Solutions and Qualicaps acquisitions.
- The company will showcase innovations in delivery, compliance, and patient outcomes.
- Roquette emphasizes its role in providing essential excipients and APIs for medications and nutraceuticals to improve patient care and effectiveness.
For the first time since completing the acquisition of IFF Pharma Solutions, Roquette will showcase its unified portfolio and strategic vision at the upcoming CPHI trade show (October 28–30).
The company will present its expanded portfolio in excipients, capsules, active pharmaceutical ingredients (APIs), drug delivery technologies, biopharmaceuticals, and nutraceuticals in Frankfurt, Germany.
In addition to the recent acquisition of IFF Pharma Solutions, Roquette purchased Qualicaps in 2023 to expand its global excipient presence.
“This milestone marks the start of an exciting new chapter in our journey as an end-to-end global leader in pharmaceutical innovation,” says Isabelle Bouvier, CEO of the Roquette Health & Pharma Solutions Business Group.
“By bringing together the strengths of three successful legacy businesses and over 75 years of expertise, we’ve expanded our ability to offer high-value drug delivery solutions that overcome modern pharma challenges.”
“We provide excipients and APIs essential to life-saving therapies — making us the industry’s trusted partner for improving, sustaining, and ultimately saving lives. We’re excited to showcase our enhanced capabilities for the first time at CPHI Frankfurt and share how we can help create a healthier future for generations to come.”
Innovation highlights
Under the banner “United for better health,” Roquette will highlight its newly integrated capabilities and technologies to advance drug delivery, compliance, and patient outcomes at booth 8.0P24. The company notes its solutions support pharmaceutical and nutraceutical manufacturers to accelerate innovation.
Specifically, it will showcase excipients and capsules designed to reduce nitrosamine risks and meet tightening global standards, such as Low Nitrite Methocel HPMC (hydroxypropyl methylcellulose, a cellulose derivative) for controlled release with nitrosamine control.
As solutions for more effective and patient-friendly medicines, the company will present Kleptose HPBCD (hydroxypropyl-beta-cyclodextrin, which is a modified sugar) for solubility and taste masking and Quali-V PHMC capsules for moisture-sensitive formulations.
In advanced coatings and capsule technologies for targeted release and process efficiencies, Roquette will highlight solutions like ReadiLycoat plant-based coating systems, alginates for anti-reflux and pH-controlled release, and Aquacoat ECD (ethylcellulose dispersion) barrier membrane coating.
